Ignite Creation Date:
2024-06-16 @ 11:52 AM
Last Modification Date:
2024-10-26 @ 3:32 PM
Study NCT ID:
NCT06459362
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-06-14
First Post:
2024-05-31
Brief Title:
Serum Cystatin C for Early Detection of Acute Kidney Injury After Primary Percutaneous Coronary Intervention
Sponsor:
Assiut University
Organization:
Assiut University
Study Overview
Official Title:
Serum Cystatin C for Early Detection of Acute Kidney Injury After Primary Percutaneous Coronary Intervention
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study aims to evaluate whether the serum levels of Cystatin C CysC can be used as early biomarkers for the identification of patients who are prone to AKI after cardiac interventional surgeries as primary percutaneous coronary intervention PCI
Detailed Description:
Acute Kidney Injury AKI is defined as an absolute increase in serum creatinine 03 mgdl 264 μmoll a percentage increase in serum creatinine 50 15-fold from baseline or a reduction in urine output documented oliguria 05 mlkghour for 6 hours Serum creatinine which is considered the gold standard currently for diagnosis of AKI remains unchanged until 50 of kidney function falls down It is affected by non-specific factors like diet age dehydration muscle mass gender and drugs There were evidences of the association between AKI and acute coronary syndrome ACS First AKI detection may be missed by cardiologists Physicians tend to disregard mild or transient serum creatinine elevation during hospital stay for ACS and they often attribute small serum creatinine increases to laboratory variations
Cystatin C CysC a cystatin protease inhibitor is less affected by non-specific factors When GFR decreases CysC begins to increase CysC was recommended to be measured in addition to creatinine in GFR estimation
Cystatin C CysC a cystatin protease inhibitor is less affected by non-specific factors When GFR decreases CysC begins to increase CysC was recommended to be measured in addition to creatinine in GFR estimation
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None